25 completed. 25 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 25 | Completed 25 |
Follow Benign Prostatic Hyperplasia: new trials by email Literature Review of Benign Prostatic Hyperplasia trials Research Report on Benign Prostatic Hyperplasia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Self-Administered Nitrous Oxide (SANO) During Transrectal Prostate Biopsy to Reduce Patient Anxiety and Pain Self-Administered Nitrous Oxide, Oxygen - Prostate Disease, Malignancy | Phase 4 | Completed | Beth Israel Deaconess Medical Center | 143 | 2021-12-12 | 2024-01-30 |
| Deprescribing Tamsulosin in Older Men Tamsulosin, Placebo - Benign Prostatic Hyperplasia, Lower Urinary Tract Symptoms | Phase 4 | Completed | University of California, San Francisco | 31 | 2021-09-18 | 2025-08-22 |
| Efficacy of Silodosin in the Treatment of Symptomatic Benign Prostatic Hyperplasia (BPH) Silodosin, Tamsulosin - Benign Prostatic Hyperplasia | Phase 4 | Completed | Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh | 141 | 2017-08-31 | 2019-09-27 |
| A Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Men With OAB Symptoms While Taking Tamsulosin Hydrochloride for Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH) Mirabegron, Placebo, Tamsulosin Hydrochloride - Benign Prostatic Hyperplasia, Overactive Bladder | Phase 4 | Completed | Astellas Pharma Global Development, Inc. | 715 | 2016-06-13 | 2024-11-12 |
| The Effects of α-adrenergic Receptor Antagonists on Choroid and Pupil Alfuzosin Hydrochloride 10 MG, Tamsulosin Hydrochloride 0.4 MG - Benign Prostatic Hyperplasia, Pupil Anomaly | Phase 4 | Completed | Kocatepe University | 63 | 2015-10-29 | 2017-05-09 |
| A Study of Tadalafil (LY450190) in Participants With Lower Urinary Tract Symptoms (LUTS) Suggestive of Benign Prostatic Hyperplasia LUTS (BPH-LUTS). Tadalafil, Placebo, Alpha1 Blocker - Benign Prostatic Hyperplasia | Phase 4 | Completed | Eli Lilly and Company | 171 | 2015-04-01 | 2017-07-02 |
| GreenLight Laser Photoselective Vaporization of the Prostate vs Bipolar Transurethral Vaporization of the Prostate; RCT Greenlight laser PVP, Bipolar TUVP - Benign Prostatic Hyperplasia | Phase 4 | Completed | Mansoura University | 120 | 2014-09-01 | 2019-06-12 |
| Efficacy and Safety of Silodosin on Nocturia for Patients With Benign Prostatic Hyperplasia Silodosin, Laboratory tests, 3-days voiding diary - Nocturia, Benign Prostatic Hyperplasia | Phase 4 | Completed | JW Pharmaceutical | 135 | 2014-01-02 | 2017-03-10 |
| Effectiveness and Safety of Silodosin in the Treatment of Benign Prostatic Hyperplasia Silodosin - Benign Prostatic Hyperplasia | Phase 4 | Completed | RECORDATI GROUP | 1036 | 2011-05-01 | 2014-04-29 |
| Comparison Between Alpha Blocker Monotherapy and 5ARI Monotherapy Following Combination Therapy in Benign Prostatic Hyperplasia (BPH) combination therapy, alpha blocker monotherapy, 5 alpha reductase inhibitor monotherapy - Benign Prostatic Hyperplasia | Phase 4 | Completed | Samsung Medical Center | 308 | 2011-01-01 | 2019-12-02 |
| Study of a α1A Adrenoceptor Selective Antagonist Silodosin to Treat Severe Benign Prostatic Hyperplasia(BPH) Silodosin - Benign Prostatic Hyperplasia | Phase 4 | Completed | JW Pharmaceutical | 100 | 2010-12-01 | 2012-03-30 |
| Combination Treatment With Doxazosin Plus TolterodineSR 2 mg Versus 4mg in Men With an Overactive Bladder (OAB) and Benign Prostatic Hyperplasia (BPH) doxazosin plus tolterodine SR - Overactive Bladder, Benign Prostatic Hyperplasia | Phase 4 | Completed | Samsung Medical Center | 83 | 2009-05-01 | 2019-12-02 |
| Solifenacin as Add-on Therapy for Overactive Bladder Symptoms in Men Treated for Benign Prostatic Hyperplasia Tamsulosin hydrochloride, Solifenacin succinate - Benign Prostatic Hyperplasia, Benign Prostatic Hypertrophy | Phase 4 | Completed | Astellas Pharma Inc | 638 | 2008-10-01 | 2013-02-15 |
| Effect of Dutasteride on HIF-1alpha and VEGF in the Prostate dutasteride - Benign Prostatic Hyperplasia | Phase 4 | Completed | Seoul National University Hospital | 40 | 2008-01-01 | 2013-06-12 |
| A Long-Term Study Examining the Treatment of Benign Prostatic Hyperplasia With Photoselective Vaporization GreenLight HPS - Benign Prostatic Hyperplasia | Phase 4 | Completed | American Medical Systems | 150 | 2007-05-01 | 2015-10-28 |
| Effect of Dutasteride on Bladder Wall Hypertrophy in Patients With Benign Prostatic Obstruction Dutasteride - Benign Prostatic Hyperplasia | Phase 4 | Completed | Samsung Medical Center | 36 | 2006-06-01 | 2009-06-11 |
| A Prospective Evaluation of the GreenLight Model 120 Laser GreenLight Model 120 Laser System - Benign Prostatic Hyperplasia | Phase 4 | Completed | Weill Medical College of Cornell University | 20 | 2006-05-01 | 2008-01-17 |
| Evaluation of Symptom-specific Goal Achievement Alfuzosin - Benign Prostatic Hyperplasia, Lower Urinary Tract Symptoms | Phase 4 | Completed | Samsung Medical Center | 130 | 2005-12-01 | 2023-11-01 |
| A Phase 4 Study With Tamsulosin OCAS to Assess Nighttime Voiding. Tamsulosin OCAS, Placebo - Benign Prostatic Hyperplasia | Phase 4 | Completed | Astellas Pharma Inc | 882 | 2005-10-01 | 2014-10-10 |
| Dutasteride and Flex Dose of Tamsulosin on as Needed Basis, to Treat Benign Prostatic Hyperplasia Tamsulosin - Benign Prostatic Hyperplasia | Phase 4 | Completed | Siami, Paul F., M.D. | 63 | 2005-09-01 | 2018-11-02 |
Showing 20 of 25. Sign in to see all of them.
Prostatic Hyperplasia (25) · Lower Urinary Tract Symptoms (6) · Urinary Bladder, Overactive (3) · Nocturia (2) · Prostatic Neoplasms (2) · Anxiety Disorders (1) · Choroid Diseases (1) · Ejaculatory Dysfunction (1) · Erectile Dysfunction (1) · Hyperplasia (1) · Hypogonadism (1) · Neoplasms (1) · Pain (1) · Prostatic Diseases (1) · Pupil Disorders (1)
Genital Diseases (25) · Genital Diseases, Male (25) · Male Urogenital Diseases (25) · Urogenital Diseases (25) · Prostatic Diseases (24) · Pathological Conditions, Signs and Symptoms (13) · Signs and Symptoms (12) · Urological Manifestations (10) · Lower Urinary Tract Symptoms (4) · Female Urogenital Diseases (3) · Female Urogenital Diseases and Pregnancy Complications (3) · Urinary Bladder Diseases (3) · Urologic Diseases (3) · Genital Neoplasms, Male (2) · Mental Disorders (2)
Tamsulosin (7) · Dutasteride (4) · silodosin (4) · alfuzosin (3) · Tadalafil (2) · 5-alpha Reductase Inhibitors (1) · Adrenergic alpha-1 Receptor Antagonists (1) · Clinical Laboratory Techniques (1) · Combined Modality Therapy (1) · Doxazosin (1) · Nitrous Oxide (1) · Oxygen (1) · Photoelectron Spectroscopy (1) · Solifenacin Succinate (1) · Testosterone (1)
Samsung Medical Center (4) · Astellas Pharma Inc (2) · JW Pharmaceutical (2) · American Medical Systems (1) · Astellas Pharma Global Development, Inc. (1) · Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh (1) · Beni-Suef University (1) · Beth Israel Deaconess Medical Center (1) · Eli Lilly and Company (1) · GlaxoSmithKline (1) · Kocatepe University (1) · London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's (1) · Mansoura University (1) · RECORDATI GROUP (1) · Sanofi (1)
United States (7) · South Korea (6) · Canada (2) · Egypt (2) · Italy (2) · Japan (2) · Bangladesh (1) · Czechia (1) · France (1) · Germany (1) · Hungary (1) · Netherlands (1) · Poland (1) · Spain (1) · United Kingdom (1)
Kyu-Sung Lee, Ph.D (4) · Ahmed M Elshal, MD (1) · Alexis Te, MD (1) · Alvin M Matsumoto, MD (1) · Benjmain N Breyer, MD, MAS (1) · Christopher R Chapple, MD (1) · Claus G Roehrborn, MD (1) · D.G. Moon, Prof (1) · D.Y. Yang, Prof (1) · G.S. Park, Prof (1) · Hassan Razvi, MD, FRCSC (1) · Heidi Rayala, MD, PhD (1)
PMID 21251673, PMID 21575967, PMID 37160401, PMID 42406401
2015 (1), K12DK111028 (1)